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INTRODUCTION 
The interrelationship between liver disease and renal dysfunction 
was recognized as early as the era of Hippocrates and this has been the 
object of a considerable amount of research since then. 
 Kidney dysfunction in liver disease can be due to different 
etiologies and can have diverse manifestations. Most of the 
abnormalities of kidney function in cirrhosis are of functional origin- 
namely, sodium retention, impaired free water excretion and renal 
vasoconstriction with decrease in renal perfusion and glomerular 
filtration rate. Renal dysfunction in chronic liver disease usually follows 
a progressive course – the final phase being Hepatorenal syndrome 
(HRS). 
There is no explanation that fully defines the complex relationship 
between the diseased liver and disturbances in kidney function, though 
substantial progress is being made in recent years regarding research in 
this aspect. 
One of the most difficult issues in the clinical evaluation of 
patients with cirrhosis is the accurate assessment of renal function. 
 2
Standard measures of renal function like blood urea nitrogen and serum 
creatinine are likely to give erroneous impressions and hence alternative 
methods to determine renal reserve must be used. 
Detection of renal insufficiency is clinically important because it 
contributes significantly to high morbidity and mortality in cirrhosis. 
Moreover, renal dysfunction is one of the most important risk factors 
when liver transplantation is being considered. Patients with cirrhosis 
and renal failure are at high risk for death while awaiting transplantation 
and have an increased frequency of complications and reduced survival 
after transplantation, as compared with those without renal failure. 
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AIM 
• To determine the usefulness of serum creatinine and creatinine 
clearance as parameters in assessing renal function abnormalities 
in patients with chronic liver disease. 
• To find if etiology of chronic liver disease has a bearing on renal 
dysfunction. 
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REVIEW OF LITERATURE 
HISTORY  
The first description of disturbances in renal function in chronic 
liver diseases was made by Frerichs and Flint in two independent reports 
from the late nineteenth century(1). These reports described the 
development of oliguria in patients with chronic liver disease in the 
absence of proteinuria and with a normal renal histology, and proposed 
the first pathophysiologic interpretation of hepatorenal syndrome by 
linking the abnormalities of renal function to the disturbances present in 
the systemic circulation.  
The coexistence of renal impairment and liver disease has even 
been mentioned by Hippocrates(2); Helwig and Schutz introduced the 
term hepatorenal syndrome in 1932 when they described a patient with 
renal failure and biliary tract disease(3). The detailed clinical description 
of HRS, however, was not made until the 1950s in studies by Sherlock, 
Papper, and Vessin.  
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RENAL ABNORMALITIES IN LIVER DISEASE 
The mechanism underlying the development of renal dysfunction 
in advanced liver disease and cirrhosis is complex and includes 
interactions between changes in the systemic arterial circulation, portal 
hypertension, activation of vasoconstrictors and suppression of 
vasodilatory factors acting on the renal circulation. 
Patients with advanced liver disease are susceptible to prerenal 
failure primarily due to disturbances in circulatory function- mainly, a 
reduction in systemic vascular resistance due to primary arterial 
vasodilatation in the splanchnic circulation, triggered by portal 
hypertension(4). The cause of this arterial vasodilatation is increased 
production or activity of vasodilator factors (particularly nitric oxide, 
carbon monoxide, and endogenous cannabinoids).  
Another factor further exacerbating renal dysfunction in these 
patients is true hypovolemia, which can be induced by gastrointestinal 
tract hemorrhage from varices; peptic ulcers or gastropathy; excessive 
diuresis; vomiting and diarrhea; or can be aggravated by large volume 
paracentesis without intravascular volume replacement. Bacterial 
infections (eg. spontaneous bacterial peritonitis) and the use of 
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nonsteroidal anti-inflammatory drugs can also precipitate pre-renal 
failure in these patients. Development of septic shock is another possible 
event which may further impair renal function. 
A) SODIUM RETENTION AND ASCITES/EDEMA 
It is the first manifestation of renal impairment in cirrhosis. The 
total amount of sodium retained is dependent on the balance between 
sodium intake and excretion. Patients may develop ascites or edema 
when sodium intake is increased (high sodium diet or administration of 
intravenous saline solution) or when they are treated with drugs that 
increase sodium reabsorption, (such as mineralocorticoids or NSAIDS. ) 
The underlying mechanism responsible for renal sodium retention 
is an increased renal tubular reabsorption of sodium in the proximal and 
distal tubules(5). This occurs even in the presence of a normal or only 
moderately reduced GFR. The two main sodium retaining systems 
responsible are the renin- angiotensin- aldosterone system (RAAS) and 
the sympathetic nervous system (SNS). These are activated as a 
homeostatic response to circulatory dysfunction. 
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B)  SOLUTE-FREE WATER RETENTION AND DILUTIONAL 
HYPONATREMIA 
Hyponatremia occurs in nearly half of patients in hospital with 
cirrhosis and ascites, and is due to the excessive retention of solute-free 
water which results from the kidney's inability to excrete it normally.  
Pathogenesis of solute-free water retention in cirrhosis seems to 
be related to three events:  
Reduced delivery of filtrate to the ascending limb of the loop of 
Henle; a reduced renal synthesis of prostaglandins; and an increased 
secretion of anti-diuretic hormone. 
The morbidity and mortality associated with hyponatremia is 
largely attributable to central nervous system disturbances. Altered 
steroid and peptide hormones in cirrhotic patients may contribute to the 
development of hyponatremia encephalopathy, symptoms of which 
overlap with hepatic encephalopathy and uremia(6).   
The appearance of hyponatraemia in cirrhotic patients, long 
regarded as a poor prognostic sign, is now identified as a marker of 
unrecognized underlying impaired renal function. 
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C) RENAL VASOCONSTRICTION 
Renal vasoconstriction leading to decreased renal perfusion is the 
renal functional abnormality that develops last in patients with cirrhosis 
and ascites. It is the consequence of the extreme underfilling of the 
systemic arterial circulation due to marked vasodilatation of the 
splanchnic circulation, which activates homeostatic vasoconstrictor 
systems, whose effect on the kidney vasculature cannot be 
counterbalanced by either renal or systemic vasodilators(7). 
Renal vasoconstriction predisposes to the development of 
hepatorenal syndrome (HRS). 
TYPES OF RENAL FAILURE IN PATIENTS WITH 
CIRRHOSIS 
A. HYPOVOLEMIA-INDUCED RENAL FAILURE 
 Hypovolemia is usually due to gastrointestinal hemorrhage or to 
fluid losses- either renal losses because of excessive diuretic therapy; or 
gastrointestinal losses as a result of diarrhea from excessive lactulose 
administration or gastrointestinal infection. Renal failure occurs soon 
after the onset of hypovolemia. 
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B. PARENCHYMAL RENAL DISEASE 
 Parenchymal renal disease should be suspected as a cause of renal 
failure when proteinuria (>500 mg of protein/day), hematuria (>50 red 
cells/high-power field), or both are present and ideally should be 
confirmed by renal biopsy, if this procedure is not contraindicated. 
 The presence of renal tubular epithelial cells in the urine sediment 
favours the diagnosis of acute tubular necrosis. 
C. DRUG-INDUCED RENAL FAILURE 
 Current or recent treatment with nonsteroidal anti-inflammatory 
drugs or aminoglycosides suggests drug-induced renal failure. 
D. HEPATORENAL SYNDROME 
Hepatorenal syndrome is an uncommon but potentially fatal 
complication of decompensated cirrhosis. It is a unique form of 
functional renal failure that often complicates advanced liver disease, 
hepatic failure or portal hypertension. It is characterized by intense 
constriction of the renal arterial vasculature with resulting oliguria and 
avid sodium retention. 
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The definition of HRS as proposed by International Ascites Club 
is,  
 “Hepatorenal syndrome is a clinical condition that develops in 
patients with chronic liver disease and advanced hepatic failure and 
portal hypertension characterized by impaired renal function and marked 
abnormalities in the arterial circulation and activity of the endogenous 
vasoactive systems. In the kidney there is marked renal vasoconstriction 
that results in low GFR. There is also vasoconstriction in other vascular 
territories such as the muscle, spleen and brain. In the splanchnic 
circulation, there is an intense arteriolar vasodilatation that results in 
reduction of total systemic vascular resistance and arterial hypotension. 
A similar syndrome can also develop in the setting of acute liver 
failure.” (8) 
Hepatorenal syndrome may occur spontaneously or in response to 
some insult such as infection, hemorrhage, or overly vigorous diuresis. 
The renal circulation in hepatorenal syndrome demonstrates 
several abnormalities: 
• reduction of renal blood flow and glomerular filtration; 
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• vasoconstriction involving the branches of the main renal 
artery and other smaller arteries; 
• cortical ischemia and instability. 
There are two patterns of hepatorenal syndrome(HRS): 
Type I HRS is characterized by a rapid and progressive 
impairment of renal function as defined by a doubling of the initial 
serum creatinine to a level higher than 2.5 mg/dl or a 50% reduction of 
the initial 24 hour creatinine clearance to a level lower than 20 ml/min in 
less than 2 weeks.  
The dominant features of type I HRS are marked renal failure 
with oliguria or anuria and increased serum levels of urea and creatinine. 
This type of HRS is frequently seen in patients with alcoholic cirrhosis, 
especially when associated with alcoholic hepatitis, but it occurs in non-
alcoholic cirrhosis as well. Precipitating factors include spontaneous 
bacterial peritonitis (SBP) and major surgical procedures.  
Most patients show signs of severe liver failure with marked 
hyperbilirubinemia, low prothrombin activity, and encephalopathy. It 
follows a fulminant course with development of oliguria and is 
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associated with very poor prognosis, with death occurring within 1 
month after presentation(4). 
In contrast to type I, type II HRS is characterized by less severe 
and stable reduction of GFR that does not meet the criteria proposed for 
type I. Patients are usually in better clinical condition than those with 
type I HRS, and their survival expectancy is markedly longer. The 
clinical picture is one of moderate stable renal disease in a patient with 
diuretic-resistant ascites due to the combination of intense sodium 
retention, reduced GFR, and marked stimulation of antinatriuretic 
systems. 
The diagnosis of HRS is one of exclusion and depends mainly on 
the level of serum creatinine, despite the fact that it does not provide an 
accurate reflection of GFR in patients with cirrhosis.  
PATHOGENESIS OF HEPATORENAL SYNDROME 
Hepatorenal syndrome is characterised by functional renal 
vasoconstriction that leads to a severe reduction in GFR with minimal 
renal histologic abnormalities. Function can be restored following 
correction of portal hypertension by liver transplantation or even when 
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the kidneys are removed and transplanted into a non-cirrhotic 
recipient(9). 
The initial abnormality in hepatorenal syndrome is peripheral and 
splanchnic arterial vasodilatation triggered by portal hypertension. This 
vasodilatation initiates adaptive responses that stimulate renal 
vasoconstriction and renal sodium and water retention.  
Various mechanisms which contribute to the pathogenesis of HRS 
are:  
1. Renin-Angiotensin-Aldosterone system (RAAS) 
   The activation of RAAS is particularly intense in patients with 
hepatorenal syndrome. 
  Plasma aldosterone levels are increased in most cirrhotic patients 
with ascites and marked sodium retention. This is due to a stimulation of 
aldosterone secretion and not due to impaired degradation as the hepatic 
clearance of aldosterone is normal or only slightly reduced in these 
patients.  
It has also been suggested that cirrhotic patients may have an 
increased tubular sensitivity to aldosterone. This explains the renal 
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sodium retention even in patients with normal levels of aldosterone. 
Hence spironolactone, a specific aldosterone antagonist is able to 
reverse sodium retention and cause natriuresis in cirrhotics. 
 Plasma renin activity is also often elevated in patients with 
decompensated cirrhosis(10). The role of angiotensin II is shown by the 
improvement of renal function in patients with HRS achieved by the 
administration of vasopressin analogues ornipressin or terlipressin 
associated with albumin, which causes a marked suppression of RAAS 
activity. 
2. Sympathetic Nervous System 
  Patients with hepatorenal syndrome have significantly higher 
plasma levels of norepinephrine than do patients without renal failure; 
and this correlates inversely with renal blood flow; suggesting that the 
sympathetic nervous system may participate in the renal 
vasoconstriction observed in patients with hepatorenal syndrome.  
Moreover, the circulating levels of neuropeptide Y, a 
neurotransmitter with a very potent vasoconstrictor action in the renal 
circulation released in the setting of a marked activation of the 
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sympathetic nervous system, are increased in patients with hepatorenal 
syndrome but not in those with ascites without renal failure. 
3. Prostaglandins  
Patients with hepatorenal syndrome have lower urinary excretion 
of PGE2 and PGI2 than do patients with ascites without renal failure, 
which suggests that a reduced renal synthesis of vasodilator 
prostaglandins may play a role in the pathogenesis of HRS(9). As 
prostaglandins are potent vasodilators in the systemic circulation, an 
increased systemic prostaglandin synthesis may contribute to arterial 
vasodilatation in cirrhosis. 
Moreover, a decrease in GFR and renal plasma flow by non 
steroidal anti-inflammatory drugs points towards a role of prostaglandin 
in maintaining normal renal perfusion. 
It has also been postulated that an imbalance between vasodilator 
and vasoconstrictor metabolites of arachidonic acid, with the latter 
dominating, contributes to irreversible vasoconstriction characterising 
HRS 
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4. Adenosine 
Intrahepatic adenosine causes an increase in portal venous blood 
flow and triggers a hepatorenal reflex (to regulate sodium and water 
excretion) which by means of increasing sympathetic activity in the 
kidney, leads to a decrease in renal blood flow and GFR(11). This 
mechanism has been recently proposed which may lead to decreased 
renal perfusion and hepatorenal syndrome. Increased synthesis of 
adenosine may be accounted by tissue hypoxia due to advanced hepatic 
dysfunction. 
5. Natriuretic Peptides 
The plasma concentration of major natriuretic hormones, namely, 
atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), is 
increased in patients with cirrhosis and ascites(9). These high levels are 
due to enhanced cardiac release and not due to a reduced hepatic or 
systemic clearance. As these peptides have powerful effects on renal 
function (mainly vasodilator and natriuretic effects) and inhibit renin 
release, increased levels may act as a homeostatic mechanism to 
counteract the effects of anti-natriuretic and vasoconstrictor systems in 
the renal circulation. 
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But the existence of increased plasma levels of ANP in cirrhosis, 
in the presence of renal sodium retention, indicates a renal resistance to 
the effects of ANP. 
6. Nitric oxide 
Nitric oxide (NO) is a powerful vasodilator agent released from 
vascular smooth muscle.  It has been proposed to be an important 
effector responsible for splanchnic vasodilation in cirrhosis. NO plays a 
role in the regulation of glomerular microcirculation by modulating the 
arteriolar tone and the contractility of mesangial cells. It facilitates 
natriuresis in response to changes in renal perfusion pressure and 
regulates renin release. 
It was found in a study that NO increased significantly with 
progression of liver disease especially in the decompensated cirrhotic 
group(12).   This result supports that NO is important in the progression 
of cirrhosis. As a result, with an increase in NO with progression of the 
liver disease, especially in ascitic cirrhosis, renal tubular and glomerular 
functions are negatively affected. 
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7. Endothelin 
The circulating levels of endothelin-1, an endothelial derived 
peptide with potent vasoconstrictor effect are also increased in cirrhosis 
probably due to an enhanced release of the peptide from the hepatic 
and/or splanchnic circulation. It has been proposed that the increased 
circulating levels and /or enhanced intrarenal production of endothelin 
may induce vasoconstriction of the renal circulation and play a role in 
the pathogenesis of hepatorenal syndrome. 
8. Endotoxins 
In cirrhotic patients the entire gastrointestinal tract becomes 
densely colonized with bacteria, presumably because of the patient's 
immunosuppressed status. Jaundice commonly observed in cirrhosis can 
promote reabsorption of endotoxin into the bloodstream. As the 
reticuloendothelial cells of the liver are likely to be compromised in 
advanced cirrhosis, absorbed endotoxin would not be completely 
destroyed by the hepatic Kupffer cells and would appear in the arterial 
circulation. The continuous reabsorption of endotoxin from the 
gastrointestinal tract into the circulation of patients with advanced 
cirrhosis leads to vasoconstriction of the renal microcirculation(13). 
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In summary, peripheral vasodilatation is the early event in the 
pathogenesis of fluid retention and hepatorenal syndrome. Following 
initial vasodilatation, maintanence of normal renal perfusion depends on 
a balance between vasodilatory and vasoconstricting factors. 
Hepatorenal syndrome represents an imbalance favouring 
vasoconstrictive over vasodilating factors, the consequences of which 
are a marked increase in renal vascular resistance, decrease in GFR, and 
avid sodium and water retention 
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DIAGNOSTIC CRITERIA FOR HEPATORENAL 
SYNDROME(14) 
MAJOR CRITERIA 
1. Chronic or acute liver disease with advanced hepatic failure and 
portal hypertension 
2. Low glomerular filtration rate as indicated by serum creatinine of  
>1.5mg/dl or 24 hour creatinine clearance <40ml/min 
3. Absence of treatment with nephrotoxic drugs, shock, infection or 
significant recent fluid losses  
4. No sustained improvement in renal function after diuretic 
withdrawal and volume expansion with 1.5 L of isotonic saline 
5. Proteinuria < 0.5 g per dL and no ultrasonographic evidence of 
obstruction or parenchymal renal disease 
ADDITIONAL CRITERIA 
1. Urine volume <500 ml/day 
2. Urine sodium <10mEq/L 
3. Urine osmolality greater than plasma osmolality 
4. Urine red blood cells <50 per high power field 
5. Serum sodium concentration < 130mEql/L 
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PSEUDO-HEPATORENAL SYNDROME  
There are various conditions in which both liver and kidneys are 
affected, but in which the liver disease does not play an etiological role 
in the pathogenesis of renal failure. These conditions constitute the so-
called “pseudo-hepatorenal syndrome”(15). 
CAUSES OF PSEUDO-HEPATORENAL SYNDROME 
1. Congenital – Polycystic disease, sickle cell anaemia, congenital 
hepatic fibrosis, nephronophthisis 
2. Toxic agents –  Drugs: tetracycline, halothane, acetaminophen, 
sulphonamides, rifampicin, allopurinol, phenytoin, 
methoxyflurane, methotrexate(high dose); and other toxic agents: 
carbon tetrachloride poisoning in industrial workers, chloroform, 
arsenic, barium 
3. Infections – Miliary tuberculosis, hepatitis B, hepatitis C, HIV, 
Schistosomiasis, septicaemia, yellow fever, leptospirosis 
4. Connective tissue disorders- SLE, Sjogren’s syndrome 
5. Circulatory alterations – Shock, heart failure 
6. Unknown aetiology – Amyloidosis, sarcoidosis, 
7. Reye’s syndrome 
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TREATMENT OF HEPATORENAL SYNDROME 
Many different therapeutic approaches have been proposed for the 
management of hepatorenal syndrome. Unfortunately, most treatment 
measures result in only transient beneficial effects on renal function, and 
are not consistently associated with improvement in patient survival.  
Liver transplantation remains the definitive treatment for 
hepatorenal syndrome; recovery of renal function is typical after that. In 
patients with either type 1 or type 2 HRS, the prognosis is poor unless 
transplant can be achieved within a short period of time. 
Transplantation in hepatorenal syndrome is associated with higher 
hospital mortality compared to those without HRS who are treated with 
transplantation(16). Thus, every attempt should be made to prevent this 
severe complication or reverse it when managing patients with cirrhosis 
and ascites.  
In recent years, new treatment strategies such as the use of 
vasoconstrictor drugs with preferential effect on the splanchnic 
circulation(V1 receptor agonists), along with plasma volume expansion, 
or insertion of TIPS, have been used with promising results. These 
treatments may prolong survival time and, therefore, act as a bridge to 
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liver transplantation in these patients. Vasoconstrictors used for 
hepatorenal syndrome include vasopressin analogues (ornipressin and 
terlipressin), somatostatin analogues (octreotide), and alpha-adrenergic 
agonists (midodrine and noradrenalin)(17). In type 1 hepatorenal 
syndrome terlipressin in combination with albumin has shown to result 
in greater improvement in renal function compared to terlipressin 
alone(18). Pharmacological treatment, when combined with 
interventional techniques, such as transjugular intrahepatic 
portosystemic shunt (TIPS), may further improve renal function in 
hepatorenal syndrome. However, TIPS is frequently associated with 
significant side effects, particularly hepatic encephalopathy and 
impairment of liver function(19), and its role in the management of 
hepatorenal syndrome needs to be established by prospective, controlled 
investigations. 
The molecular adsorbent recirculating system (MARS) has been 
used in the treatment of acute decompensation of chronic liver disease, 
acute liver failure and hepatorenal syndrome. This liver support system 
utilizes either intermittent (6-8 h daily) or continuous hemodialysis with 
dialysate enriched with 20% human serum albumin as a means to 
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remove albumin-bound toxins (bilirubin, bile acids, fatty acids, 
tryptophan, aromatic amino acids, and copper)(20). 
EVALUATION OF PATIENTS WITH CIRRHOSIS AND RENAL 
FAILURE 
 Renal function should be routinely monitored in all patients with 
advanced cirrhosis, especially those with ascites. Patients who have 
ascites, particularly those with hyponatremia, bacterial infections, 
gastrointestinal bleeding, or severe sodium retention, are at high risk for 
renal failure, as are all patients hospitalized for acute decompensation of 
cirrhosis(21).  
 Other than blood urea nitrogen, serum creatinine and creatinine 
clearance, evaluation of renal function should also include  
Serum electrolytes - hyponatremia is common; potassium 
sparing diuretics shpuld be discontinued 
to precvent hyperkalemia ; 
Urine analysis - significant proteinuria and urine 
sediment abnormalities usually indicate 
parenchymal renal disease 
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Renal ultrasonography - abnormal renal ultrasonograms indicate 
chronic parenchymal renal disease 
Renal biopsy - helpful when parenchymal renal disease 
is suspected because of proteinuria, 
hematuria, or both and is also helpful in 
deciding on simultaneous kidney 
transplantation in candidates for liver 
transplantation. Renal biopsy is 
contraindicated if severe coagulation 
abnormalities are present. 
 The evaluation of patients with cirrhosis and renal failure should 
also include an assessment of liver function, as well as the exclusion of 
possible bacterial infections. The patient’s medications should be 
reviewed, and diuretics should be discontinued, since these agents may 
either be the cause of renal failure or contribute to the impairment of 
renal function. 
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DIFFERENTIAL DIAGNOSIS OF RENAL FAILURE IN LIVER 
DISEASE 
The differential diagnosis of renal dysfunction in advanced liver 
disease includes pre-renal failure, intrinsic renal failure and hepatorenal 
syndrome.  
The diagnostic evaluation relies upon clinical and laboratory data, 
including urine analysis, as well as ultrasonographic and radiological 
investigations.   
 Renal biopsy generally is not necessary for the diagnosis of acute 
renal failure in liver disease, but is useful in excluding an intrinsic renal 
disorder(22).  A history of gastrointestinal hemorrhage, vomiting or 
diarrhea, exposure to nephrotoxic medication, or features suggestive of 
sepsis may provide important diagnostic information.  
Arterial hypertension, which is an unexpected finding in patients 
with cirrhosis, suggests glomerulonephritis. Purpura, arthralgia, 
weakness, Raynaud’s syndrome, or leg ulcers suggest cryoglobulinemia 
associated with hepatitis C. The presence of antibodies to hepatitis C 
virus and hepatitis C virus RNA, high concentrations of cryoglobulins, 
positive rheumatoid factor assays, and low concentrations of 
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complement suggest hepatitis C virus-associated cryoglobulinemic 
glomerulonephritis(23).  
Diagnostic information may be obtained from urine analysis. 
Pigmented granular casts are typical of ischemic and toxic acute renal 
failure and red cell casts of glomerulonephritis. Patients with renal 
azotemia due to acute or subacute glomerulonephritis have significant 
proteinuria (around 3 g/d). In contrast, proteinuria is absent or moderate 
in other causes of acute renal failure. 
Urine indices such as osmolality, sodium concentration, 
urine:plasma osmolality ratio (U/Posm) and urine:plasma creatinine 
ratio (U/Pcreat), are useful theoretical tools for differential diagnosis of 
the three principal causes of acute renal failure in liver disease. 
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TABLE I 
DIFFERENTIATION OF HRS FROM PRE-RENAL AZOTEMIA 
AND ACUTE TUBULAR NECROSIS (ATN)(24,25) 
Differentiating 
characteristic 
HRS 
Pre-renal 
azotemia 
Acute tubular 
necrosis 
History of 
precipitating event 
May/ may 
not be 
present 
Invariably 
present; loss of 
fluids evident 
Present with fluid 
loss, shock, sepsis, 
or nephrotoxic 
drugs 
Urine output Oliguria Oliguria Oliguria, anuria 
Urinary sediment Absent Hyaline casts Granular casts, 
cellular debris 
Urinary sodium 
(meq/l) 
< 5 < 10 > 20 
Urine to plasma 
osmolality ratio 
> 1.5 > 1.5 1 
Urine to plasma 
creatinine ratio 
> 40 > 40 < 20 
Response to 
plasma expansion 
Absent Good Absent 
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The course of renal response to fluid challenge or vasoconstrictor 
therapy can also help differentiate causes of acute azotemia in liver 
disease.  Rapid improvement in renal function in response to fluid 
challenge denotes pre-renal failure, whereas mild or no improvement 
represents acute tubular necrosis or hepatorenal syndrome. 
Vasoconstrictor agents such as terlipressin or noradrenalin can 
sometimes be used to differentiate between hepatorenal syndrome  and 
acute tubular necrosis, with improvement of GFR in favour of 
hepatorenal syndrome(26).  
 Duplex Doppler ultrasonography, is another sensitive method of 
assessing intrarenal hemodynamics in patients with cirrhosis and ascites, 
in whom the renal artery resistive index is significantly increased and 
correlates with GFR and plasma renin activity(27). 
PROGNOSIS OF RENAL FAILURE IN CIRRHOSIS 
The prognosis for patients with cirrhosis and renal failure is 
poor(28). The overall survival rate is approximately 50 % at 1 month and 
20 % at 6 months .This extremely poor outcome is probably related to 
the combination of liver and renal failure, as well as to associated 
complications.  
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 However, survival rates can differ according to the type of renal 
failure. The hepatorenal syndrome is associated with the worst 
prognosis. The great majority of patients with hepatorenal syndrome 
have a poor short-term outcome unless they undergo liver 
transplantation. Mortality is higher with type 1 hepatorenal syndrome 
than with type 2 (median survival, 1 month vs. 6 months). 
PREVENTION OF RENAL FAILURE IN ADVANCED LIVER 
DISEASE 
Two different strategies can be used to prevent hepatorenal 
syndrome.  
The first is to perform liver transplantation in patients with 
cirrhosis and ascites before hepatorenal syndrome develops. The 
identification of factors associated with a high risk of developing HRS 
and the use of duplex Doppler ultrasonography to assess the renal artery 
resistive index in the follow-up of these patients may be useful for this 
purpose. 
The second strategy is to prevent the development of renal 
impairment in patients by avoiding the precipitating factors i.e. prompt 
management of bleeding and infection.  
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Spontaneous bacterial peritonitis is a precipitating factor of HRS. 
SBP stimulates the production of the proinflammatory cytokine, tumor 
necrosis factor-alpha, which is known to induce vasorelaxant 
mechanisms in arteries(29). Thus, the SBP induced TNF–mediated 
activation of vasodilator mechanisms may enhance preexisting systemic 
vasodilation (and arterial hypovolemia) and precipitate hepatorenal 
syndrome. It has been hypothesized that in patients with SBP, 
simultaneous intravenous administration of albumin and antibiotics 
could prevent the sepsis-induced decrease in effective arterial blood 
volume and resulting HRS. 
 A recent study has indicated that the development of  hepatorenal 
syndrome in patients with SBP can be effectively prevented by the 
addition of albumin to antibiotic (cefotaxime) therapy (1.5 g/kg human 
albumin intravenously at the time of diagnosis of the infection and 1 
g/kg intravenously 48 hr later)(30). The proportion of patients who 
developed HRS and the in-hospital mortality was significantly lower in 
the cefotaxime-plus-albumin group than in the cefotaxime alone. The 
beneficial effect of albumin is probably related to its ability to prevent 
circulatory dysfunction and subsequent activation of vasoconstrictor 
systems that occur during infection(30). 
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OTHER RENAL ABNORMALITIES IN CIRRHOSIS 
• GLOMERULAR DISEASES 
            In association with hepatitis B and C viruses and alcoholic liver 
disease 
• RENAL TUBULAR ACIDOSIS 
           May occur in cirrhosis of different etiologies: primary biliary 
cirrhosis, autoimmune hepatitis and alcoholic cirrhosis 
• DRUG INDUCED RENAL DYSFUNCTION 
          Especially with NSAIDs, aminoglycosides, diuretics or 
vasodilators 
• ACUTE TUBULAR NECROSIS 
          Due to volume depletion as in sepsis or hypovolemic shock or due 
to nephrotoxic drugs 
• IMPAIRED SODIUM AND POTASSIUM EXCRETION 
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MATERIALS AND METHODS 
INCLUSION CRITERIA 
This study included patients with chronic liver disease being 
treated as in-patients in the Department of General Medicine, 
Government Stanley Hospital, Chennai. 
Evidence for chronic liver disease being defined by:  
• a compatible Clinical profile (signs of liver cell failure or 
reduced liver span) along with  
Biochemical (altered liver function tests, reversal of 
albumin-globulin ratio) or 
   Sonographic evidence (altered echotexture of liver) 
  OR 
• Tissue diagnosis (positive liver biopsy for cirrhosis) 
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EXCLUSION CRITERIA 
• Elderly patients (>60 years) 
• Overt renal failure (S. creatinine >1.5) 
• Known primary renal disease 
• Diabetes mellitus / Hypertension 
• Grade 4 hepatic encephalopathy 
• Recent gastrointestinal bleed 
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METHODOLOGY 
Inpatients in the medical ward/IMCU admitted with chronic liver 
disease with seemingly normal renal function were included in this 
analytical study which was conducted from June 2009 to October 2009. 
Data regarding demographic variables (age, weight), clinical 
features (presenting complaints, ascites, jaundice, encephalopathy, 
history of alcoholism, etc) and clinical examination findings of liver cell 
failure were collected using a proforma (attached in Annexure). 
Diuretics were withheld for 3 days before carrying out lab 
investigations. 
Lab investigations including complete Liver function test, Renal 
function tests, Viral marker for hepatitis B, Urine analysis, 24 hour urine 
volume and Urine creatinine was done and results noted. 
Patients were subjected to an ultrasound scan of abdomen with 
regard to liver echotexture and size, evidence of splenomegaly or portal 
hypertension, presence of ascites and kidney pathology. 
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Creatinine clearance for the patient was calculated by the formula  
(URINE CREATININE / SERUM CREATININE MULTIPLIED BY 
24 HOUR URINE VOLUME). 
(UCr / PCr) x V 
This was divided by 1440 to get the value in ml/minute. 
Creatinine clearance was also calculated using the Cockcroft and 
Gault formula(CGF). 
(140- AGE) x WEIGHT  /    (SERUM CREATININE x 72) 
This value is to be multiplied by 0.85 if the patient is female. 
Comparison between serum creatinine and creatinine clearance 
calculated by these two methods were done.  
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OBSERVATIONS AND ANALYSIS 
50 patients with chronic liver disease were enrolled in the study. 7 
patients did not satisfy inclusion criteria and were excluded. So, a total 
of 43 patients were included. 
The following observations were made: 
AGE AND SEX: 
Age of the patients ranged from a minimum of 22 years to a 
maximum of 58 years. The mean age was 42.14 years. The age 
distribution is as follows: 
AGE GROUP NUMBER OF PATIENTS 
Less than 30 years 2 
30 to 39 years 9 
40 to 49 years 24 
Above 50 years 8 
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Patients above 60 years were excluded as GFR decreases with 
age. False low GFR thus calculated would interfere with the findings of 
this study.  
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Of the patients included in the study 35 were male, while 
remaining 8 were female. 
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ETIOLOGY: 
Out of the 43 patients of cirrhosis, the cause of liver disease was 
attributed to alcoholism in 21 patients. 6 patients were found to be 
positive for Hepatitis B surface antigen. One patient was a case of 
Wilson’s disease and another patient was found to have autoimmune 
hepatitis.  
In the other 14 patients, causative etiology could not be 
ascertained. 
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ETIOLOGY NO. OF PATIENTS PERCENTAGE 
ALCOHOLISM 21 48.83 % 
HEPATITIS B 6 13.95 % 
WILSON’S 1 2.33 % 
AUTO IMMUNE 
HEPATITIS 1 2.33 % 
UNKNOWN 14 32.56 % 
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ASSESSMENT OF RENAL FUNCTION BY DIFFERENT 
METHODS 
Out of the 43 patients, renal function was assessed by serum 
creatinine, creatinine clearance from timed urine collection [(UxV)/P] 
and creatinine clearance by Cockcroft Gault formula(CGF). 
The patients were grouped into three based on their creatinine 
clearance [(UxV)/P]. Group I having values more than 60 ml/mt, Group 
II 30-60 ml/mt and Group III less than 30 ml/mt. 
 GROUP I GROUP II 
GROUP 
III 
BLOOD UREA mg/dL 22.43 22.42 22.4 
SERUM CREATININE mg/dL 0.90 1 1.2 
24 HOUR URINE VOLUME ml 2010.71 1136.84 690 
CREATININE CLEARANCE       
(UxV / P) ml/mt 85.33 43.41 18.55 
CREATININE CLEARANCE       
(CG FORMULA) ml/mt 85.02 63.87 44.90 
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BLOOD UREA LEVELS 
There was no significant variation in blood urea levels in all the 
three groups, suggesting that estimation of blood urea will not be of 
much use in determining renal impairment. 
Mean blood urea level was 22.42 mg/dL. 
SERUM CREATININE 
 Only patients with creatinine levels less than 1.5 mg/dL were 
included in this study. It was seen that in 7 patients with creatinine 
clearance less than 30 ml/mt, serum creatinine levels failed to rise above 
1.2 mg/dL, suggesting that moderate to severe renal dysfunction may be 
masked by seemingly normal creatinine levels. 
The mean serum creatinine level was 1.01 mg/dL. 
24 HOUR URINE VOLUME 
Patients with greater amount of renal impairment were found to 
have lesser urine output, thus suggesting that eliciting history of oliguria 
in a patient with normal serum creatinine levels should call for a high 
index of suspicion of renal dysfunction.  
The mean 24 hour urine volume was 1317.44 ml. 
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MEASURED CREATININE CLEARANCE BY TIMED URINE 
COLLECTION: 
The patients were grouped into three based on their creatinine 
clearance: 
Group Creatinine clearance No. of patients 
Group I >60 ml/minute 14 
Group II 30-60 ml/minute 19 
Group III <30 ml/minute 10 
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Measurement of creatinine clearance using the Cockcroft Gault 
formula (CGF) showed significantly higher values, suggesting 
overestimation of GFR by this method. 
CREATININE 
CLEARANCE 
BY   (U x V) /  P 
BY COCKCROFT 
GAULT FORMULA 
<20 ml/mt 6    (13.95 %) 0   (0 %) 
20-40 ml/mt 12  (27.90 %) 4    (9.30 %) 
40-60 ml/mt 11  (25.58 %) 11  (25.58 %) 
60-80 ml/mt 5    (11.63 %) 17   (39.54 %) 
>80 ml/mt 9     (20.93 %) 11   (25.58 %) 
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Eighteen percent ie, five out of the twenty-eight patients with 
creatinine clearance more than 60 ml / minute by Cockcroft gault 
formula were found to have creatinine clearance values less than 40 
ml/minute when done by timed urine collection. 
P value calculated was found to be less than 0.0001 which is 
statistically significant. 
RENAL FUNCTION ACCORDING TO ETIOLOGY 
NUMBER OF PATIENTS 
ETIOLOGY 
GROUP I GROUP II GROUP III 
ALCOHOLISM 5 10 6 
HEPATITIS B 3 2 1 
WILSON’S 0 0 1 
AUTO IMMUNE 0 1 0 
UNKNOWN 6 6 2 
 
Out of the 21 alcoholic liver disease patients, only 5 (20 %) had 
creatinine clearance more than 60 ml/minute, whereas 3 (50%) out of 
the 6 HBsAg positive patients had creatinine clearance more than 60 
ml/minute. 
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SERUM ALBUMIN AND RENAL FUNCTION 
Mean serum albumin was 3.37 mg/dL. The distribution of serum 
albumin in the three groups was as follows: 
SERUM ALBUMIN  
(mg/dL) GROUP I GROUP II GROUP III
>3.5 8 2 0 
3.2-3.5 4 14 3 
<3.2 2 3 7 
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Average serum albumin (mg/dL) in the three groups was: 
 GROUP I  -  3.59 
 GROUP II  - 3.34 
 GROUP III  - 3.11 
Serum albumin was found to have direct correlation with renal 
function, ie, patients with higher rates of creatinine clearance were seen 
to have higher albumin levels. 
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SERUM BILIRUBIN AND RENAL FUNCTION 
The distribution of serum bilirubin levels in the three groups were 
as follows:  
SERUM BILIRUBIN 
(mg/dL) GROUP I GROUP II GROUP III 
< 1.2 2 2 3 
1.2 – 2 8 12 4 
> 2 4 5 3 
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 The mean bilirubin was 1.64 mg/dL. Average bilirubin levels in 
the 3 groups: 
Group I - 1.67 
Group II - 1.61 
Group III - 1.64 
Serum bilirubin levels were found to have no significant 
correlation with renal function. 
ULTRASOUND FINDINGS 
Ultrasound abdomen was done in all of the 43 patients. Findings 
of splenomegaly and altered echotexture of liver were uniformly seen in 
all these patients. 
  Ascites was present in 38 out of the 43 patients. It was noted that 
the patients without ascites had relatively better renal function; ie, all the 
5 patients belonged to group I ( Creatinine clearance > 60 ml/mt). thus 
suggesting that ascites may be one of the first changes in worsening 
renal function. 
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Liver was shrunken in size in 41 of the study subjects. The 
remaining 2 showed changes of malignant transformation.  
Kidney size and corticomedullary differentiation was normal in 
all patients.  
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DISCUSSION 
This study followed 43 patients with chronic liver disease with 
special emphasis on renal function. 
Many patients with cirrhosis and ascites will have a glomerular 
filtration rate of less than 60 ml/minute but a normal serum creatinine 
level. Our study showed that serum creatinine alone in patients with 
advanced liver disease is of limited value for identification of renal 
dysfunction. This is in agreement with the findings in a study by 
McAulay et al(31). 
Another prospective study of a large number of cirrhotic patients 
by Papadakis and Arieff also indicated that the glomerular filtration 
rate can be very low even when the serum creatinine is less than 1.0 
mg/dL(32). 
The level of serum creatinine required for the diagnosis of HRS is 
1.5 mg/dL, in the absence of diuretic therapy. Although this value may 
seem rather low, patients with cirrhosis and a serum creatinine above  
1.5 mg/dL have a GFR below 30 ml/min(33). Hence, patients with 
creatinine levels more than 1.5 mg/dL were excluded from our study.  
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Our study also shows that calculating creatinine clearance by 
Cockcroft Gault formula overestimates renal function. This is probably 
due to discrepancies in weight due to fluid retention which is one of the 
consequences of renal impairment in cirrhotics.  As weight is one of the 
variables in the numerator of the formula, an increase in weight due to 
edema or ascites will give a spuriously high creatinine clearance. The 
study by McAulay also supports this finding(31). This overestimation of 
renal function was highest in patients with lower GFR, which was 
observed in our study also. 
MacAulay et al observed that among the Cr-based GFR 
formulas, the MDRD formula had the best overall accuracy. This 
formula developed by the Modification of Diet in Renal Disease 
(MDRD) Study Group is based on the patient's Creatinine levels, age, 
sex, race and serum urea nitrogen and serum albumin levels and it 
showed a larger proportion of agreement with radionuclide GFR in 
patients with advanced liver disease. MacAulay summarised that in 
clinical practice, the MDRD is the best formula for detection of 
moderate renal dysfunction among those with cirrhosis(31). But the above 
mentioned study didn’t include any formulas requiring urine collection. 
As MDRD formula requires web based calculations, it will be 
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impractical to rely on it as a parameter of assessing renal function in a 
resource limited setup. 
Measured creatinine clearance from timed urine collections is a 
relatively inexpensive, accessible method used in clinical practice. Our 
study showed that it provides a better estimate of renal reserve than 
serum creatinine or predicted creatinine clearance by Cockcroft-Gault 
formula.   
A systematic review and meta-analysis of patients with cirrhosis 
by Proulx et al showed that although creatinine clearance measured by 
timed urine collections overestimates GFR in patients with liver 
cirrhosis, it is a preferable method in clinical practice, as it is more 
reliable than serum creatinine or predicted creatinine clearance (by 
CGF)(33). This overestimation is substantial especially in the low GFR 
range where important decisions relative to drug dose adjustment, the 
staging of CKD and the pre-liver transplant evaluation may be required. 
The meta-analysis proved that direct measurement of GFR using 
inulin clearance (CIn) is the most accurate estimate of renal reserve(34). 
But in routine clinical practice, GFR estimation by this method is not 
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very feasible because of the complexity, expense and limited availability 
of testing and overall patient inconvenience. 
 Few articles have examined alternative GFR markers using 
cystatin C or radioisotopes and two studies support the use of the renal 
clearance of either [51Cr]EDTA or [125I]iothalamate to estimate GFR in 
patients with liver cirrhosis, which again will be impractical in our 
setup. 
The study by Papadakis and Arrief was a prospective evaluation 
of 23 non-azotemic cirrhotic patients with ascites over a three-year 
interval(32). It  showed that the serum creatinine levels frequently failed 
to rise above normal even when the glomerular filtration rate was very 
low (less than 25 ml/minute), and creatinine clearance overestimated 
inulin clearance. However, this study also suggested that creatinine 
clearance was an aid in determining true glomerular filtration rate(when 
inulin clearance was not available) and may be a useful clinical test in 
the evaluation of renal insufficiency in cirrhotic patients with normal 
serum creatinine values. 
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Our study has shown a direct correlation between serum albumin 
levels and renal function. This may also indicate that renal dysfunction 
is more with advancing classes of Child-Pugh classification. The 
correlation with albumin levels has also been noted in a study by 
Amrapurkar et al(35). This latter study also denoted direct correlation 
between chronicity of liver disease and renal dysfunction. It also showed 
a higher mortality in patients with lower creatinine clearance especially 
with hepatorenal syndrome.  
But a study by Hampel et al showed no significant difference in 
serum levels of albumin and did not consider it as a risk factor for renal 
dysfunction(36). The same study showed no significant differences in 
age, etiology of cirrhosis, serum levels of bilirubin, prothrombin time, 
encephalopathy, bacteremia, urinary tract infection, or occurrence of 
esophageal variceal bleeding in cirrhotic patients with or without renal 
dysfunction. Patients who developed renal  dysfunction were more 
likely to have ascites. This was seen in our study also.  
The study by Hampel et al also showed aminoglycoside 
treatment as a strong risk factor for renal  dysfunction, independent of 
the severity of liver disease or spontaneous bacterial peritonitis(36). 
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Our study showed that patients with alcoholic liver disease were 
predisposed to develop renal impairment when compared with liver 
disease of other etiologies. Only 20 % of alcoholic patients had a 
creatinine clearance of more than 60 ml/mt as compared to 50 % of  
cirrhotic patients due to hepatitis B.  
Our study showed that standard measures of renal function, 
namely blood urea and serum creatinine should not be the only criteria 
to assess renal reserve in chronic liver disease, as they may seem normal 
even in gross renal dysfunction.  
Blood urea nitrogen levels may also vary in the absence of GFR 
changes. The reasons for this being : 
1) Blood urea levels may be lower than expected in patients 
with liver disease because of reduced hepatic synthesis. 
2)  Blood urea levels may also increase because of 
gastrointestinal hemorrhage or catabolic states.  
Hence, blood urea levels cannot be relied on to assess renal 
dysfunction. 
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Similarly, serum creatinine measurements may underestimate 
changes in GFR(37) because of  
1) decreased synthesis of creatine from liver, and more 
importantly, 
2) decreased endogenous production of creatinine in cirrhotics 
due to decreased muscle mass as a result of severe wasting.  
 Hence, to check for renal dysfunction in advanced liver disease, 
routine tests like blood urea and serum creatinine will be insufficient. 
Other methods like measured creatinine clearance should be employed 
to get an accurate picture of the renal status. 
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CONCLUSIONS 
• In chronic liver disease, serum creatinine alone is not a reliable 
marker to assess renal dysfunction. 
• Calculating creatinine clearance by using Cockcroft Gault 
formula overestimates renal function in cirrhotics. 
• Creatinine clearance measured by timed urine collections should 
be done routinely to assess renal reserve in advanced liver 
disease. 
• Alcoholism appears to have adverse effect on renal function when 
compared with other etiologies of cirrhosis. 
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PROFORMA 
1. NAME: 
2. AGE: 
3. SEX: 
4. WEIGHT (IN KG): 
5. ETIOLOGY OF CHRONIC LIVER DISEASE: 
ALCOHOLISM/ HEPATITIS B/ WILSON’S/ 
AUTOIMMUNE HEPATITIS/ UNKNOWN 
6. CLINICAL FEATURES: 
-JAUNDICE/ HEMETEMESIS/ MALENA/ 
ABDOMINAL DISTENSION/ PEDAL EDEMA/ 
DECREASED URINE OUTPUT/ FEVER OR OTHER 
SIGNS OF SBP 
-ASCITES/ HEPATOMEGALY/ SPLENOMEGALY/ 
SIGNS OF LIVER CELL FAILURE 
7. HISTORY OF ALCOHOLISM: YES/ NO 
8. INVESTIGATIONS: 
• LIVER FUNCTION TESTS- 
SERUM BILIRUBIN 
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TOTAL PROTEIN 
SERUM ALBUMIN 
SGOT/SGPT 
• RENAL FUNCTION TESTS- 
BLOOOD UREA NITROGEN 
SERUM CREATININE (P) 
SERUM ELECTROLYTES 
• URINE ANALYSIS- 
24 HOUR URINE VOLUME (V) 
24 HOUR URINE CREATININE (U) 
• CREATININE CLEARANCE- 
1. (U x V) / (P x 1440) 
2. COCKCROFT GAULT FORMULA 
(140-AGE) x WEIGHT / ( P x 72) 
 X .85 ( IF FEMALE) 
• HBsAG- POSITIVE/ NEGATIVE 
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• ULTRASOUND ABDOMEN- 
LIVER – SIZE/ ECHOTEXTURE 
SPLEEN- SIZE 
ASCITES 
KIDNEYS-  
 SIZE 
CORTICOMEDULLARY 
DIFFERENTIATION 
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MASTER CHART 
S.Cr 24Hr Ur Ur.Cr CR CL CR CL USG ABD S. 
No NAME Age Sex Wgt Etio S.Br T.Pr S.Alb BUN P V U (U x V) / P (CGF) Asc Lvr Sply Kidy 
1 Jayavel 32 M 50 HepB 1.5 7 4 22 0.8 1900 54.00 89.06 93.75 Y S Y N 
2 Suresh 40 M 58   X 1.8 6 3 22 1 2000 57.50 79.86 80.56 Y S Y N 
3 Munusamy 40 M 60 Alc 1.2 6.8 3.7 26 0.9 1950 60.75 91.41 92.59 Y S Y N 
4 Lakshmanan 38 M 52 HepB 1 6.4 3.8 20 0.8 2100 49.50 90.23 92.08 N S Y N 
5 Ibrahim 42 M 70    X 1.3 6.9 3.6 26 1 2300 65.00 103.82 95.28 N S Y N 
6 Rajavelu 40 M 55 Alc 1 7 4 18 1 2500 49.00 85.07 76.39 N S Y N 
7 Malaikonda 45 M 48 Alc 1.6 6 3.5 22 0.8 1700 53.00 78.21 79.17 Y S Y N 
8 Pichaiya 43 M 55    X 1.4 6.5 3.8 28 0.9 2000 55.00 84.88 82.33 Y S Y N 
9 Chandra 44 F 58    X 2 6 3.5 22 0.8 1900 50.00 82.47 82.17 N S Y N 
10 Loganathan 40 M 60 Alc 2.2 6.2 3.6 18 0.9 1800 58.00 80.56 92.59 Y S Y N 
11 Fathima 38 F 56 HepB 1.8 6.4 3.8 20 1 2000 57.00 79.17 79.33 Y S Y N 
12 Murugesan 40 M 58    X 1.2 6.1 3.1 22 0.8 2200 55.00 105.03 100.69 N S Y N 
13 Kuppusamy 42 M 50 Alc 3 6.2 3.5 26 1 1900 52.00 68.61 68.06 Y S Y N 
14 Jayanthi 41 F 58    X 2.4 6 3.4 22 0.9 1900 52.00 76.23 75.32 Y S Y N 
15 Rajan 44 M 53 Alc 2 5.8 3.4 28 0.8 1500 46.00 59.90 88.33 Y S Y N 
16 Palayam 38 M 49    X 1 6.2 3 24 1 900 56.00 35.00 69.42 Y S Y N 
17 Kumari 45 F 55 X 1.4 6 3.5 20 0.8 1300 44.00 49.65 77.11 Y S Y N 
18 Irulandi 50 M 61 Alc 1.7 5.5 3.2 22 1 800 63.00 35.00 76.25 Y S Y N 
19 Selvam 40 M 50 Alc 0.8 6 3.3 18 0.8 1000 57.50 49.91 86.81 Y S Y N 
20 Tamizhselvan 42 M 49 Alc 1.5 5.8 3.4 20 1 1500 53.75 55.99 66.69 Y S Y N 
21 Arumugam 48 M 53 Alc 1.2 6 3.5 28 0.9 1400 46.25 49.96 75.25 Y S Y N 
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S.Cr 24Hr Ur Ur.Cr CR CL CR CL USG ABD S. 
No NAME Age Sex Wgt Etio S.Br T.Pr S.Alb BUN P V U (U x V) / P (CGF) Asc Lvr Sply Kidy 
22 Subbaiya 38 M 45 HepB 1.6 6 3.2 22 1 750 61.50 32.03 63.75 Y N Y N 
23 Sivagami 50 F 50 X 2.3 6.2 3 24 1.4 1200 59.00 35.12 37.95 Y S Y N 
24 John 38 M 45 X 1.2 5.8 3.3 20 1 1250 64.50 55.99 63.75 Y S Y N 
25 Dilli Babu 50 M 50 Alc 2.6 6.2 3.5 18 1 900 56.00 35.00 62.50 Y S Y N 
26 Kesavan 45 M 47 Alc 1.4 5.6 3.2 26 1.2 1200 54.50 37.85 51.68 Y S Y N 
27 Kalaiselvi 38 F 35 AIH 2.4 6 3.4 28 0.8 950 55.00 45.36 52.68 Y S Y N 
28 Elumalai 40 M 40 Alc 1.6 6 3.6 26 1.2 1100 58.00 36.92 46.30 Y S Y N 
29 Jayapal 45 M 50 Alc 1.2 5.8 3.3 24 1 1300 47.00 42.43 65.97 Y S Y N 
30 Mohd. Iqbal 28 M 38 HepB 1.6 5.6 3.1 18 0.9 1200 55.00 50.93 65.68 Y S Y N 
31 Anbumani 30 M 40 X 1.4 5.8 3.3 22 1 1250 48.00 41.67 61.11 Y S Y N 
32 Palani 35 M 38 X 1.5 6.1 3.7 18 1 1100 58.00 44.31 55.42 Y S Y N 
33 Subramani 50 M 45 Alc 2.2 6.2 3.5 20 1.2 1000 55.00 31.83 46.88 Y S Y N 
34 Natarajan 46 M 41 Alc 1.2 5.8 3.1 24 1.2 500 45.50 13.17 44.61 Y S Y N 
35 Kannan 50 M 40 X 1.8 5.7 3 18 1.4 800 40.00 15.87 35.71 Y S Y N 
36 Nadiya 55 F 50 X 1.2 6 3.2 22 1.2 500 44.00 12.73 41.81 Y S Y N 
37 Elangovan 50 M 42 Alc 3.2 6 3.4 26 1.3 800 50.00 21.37 40.38 Y S Y N 
38 Velan 45 M 43 Alc 1 5.8 3 22 1.2 900 51.00 26.56 47.28 Y S Y N 
39 Santhosh 24 M 34 Wilsn 1.8 6.2 3.1 20 1.2 400 48.00 11.11 45.65 Y S Y N 
40 Guna 43 F 41 HepB 2 5.5 3 22 1 600 43.00 17.92 46.95 Y N Y N 
41 Ali Akbar 40 M 44 Alc 1 6 3.1 26 0.9 750 44.00 25.46 67.90 Y S Y N 
42 Karthikeyan 42 M 40 Alc 2.2 5.7 3.2 20 1.4 850 43.00 18.13 38.89 Y S Y N 
43 Shahul  58 M 42 Alc 1 5.8 3 24 1.2 800 50.00 23.15 39.86 Y S Y N 
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KEY TO MASTER CHART 
1. Name of patient 
2. Age (in years) 
3. Sex 
4. Weight (in kg) 
5. Etiology of chronic liver disease: Etio 
Alcoholism   Alc 
Hepatitis B   HepB 
Wilson’s   Wilsn 
Autoimmune hepatitis AIH 
Unknown    X 
6. Serum Bilirubin S. Br 
7. Total Protein  T. Pr 
8. Serum Albumin S. Alb 
9. Blood Urea Nitrogen BUN 
10.  Serum Creatinine ( P )  
11.  24 Hour Urine Volume ( V ) 
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12.  Urine Creatinine ( U ) 
13.  Creatinine clearance   CR CL 
= ( U x V ) / ( P x 1440 ) 
14.  Creatinine clearance ( Cockcroft Gault formula CGF) 
= (140 – age) x weight / ( P x 72)          x 
0.85 if female 
15. Ultrasound abdomen 
Ascites (Asc)  Yes  Y 
    No   N 
Liver (Lvr)   Shrunken S 
    Normal N 
Splenomegaly (Sply) Yes  Y 
    No  N 
Kidney (Kidy)  Normal N 
